1. Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
- Author
-
Kuo TY, Lien CE, Lin YJ, Lin MY, Wu CC, Tang WH, Campbell JD, Traquina P, Chuang YS, Liu LT, Cheng J, and Chen C
- Subjects
- Animals, Cricetinae, Adjuvants, Immunologic, Antibodies, Neutralizing, Antibodies, Viral, SARS-CoV-2, COVID-19 prevention & control, COVID-19 Vaccines immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern negatively impact the effectiveness of vaccines. In this study, we challenge hamsters with the delta variant after 2- or 3-dose inoculations with SARS-CoV-2 vaccines constructed from stabilized prefusion spike proteins (S-2P) of Wuhan (W) and beta (B) variants. Compared to 3 doses of W S-2P, 2 doses of W S-2P followed by a third dose of B S-2P induced the highest neutralizing antibody titer against live SARS-CoV-2 virus and enhanced neutralization of omicron variant pseudovirus. Reduced lung live virus titer and pathology suggested that all vaccination regimens protect hamsters from SARS-CoV-2 delta variant challenge., Competing Interests: Potential conflicts of interest. C. C., T.-Y. K., C.-C. W., W.-.H. T, C.-E. L., Y.-J. L., and M.-Y. L. are coinventors for US provisional patent applications 63/240,408, 63/240,080, 63/248,189. and 63/251,741. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF